Enterprise Therapeutics, a portfolio company of IP Group, announced positive Phase 2 trial results for ETD001, its inhaled treatment for cystic fibrosis. The trial showed a meaningful improvement in lung function over 28 days in patients with the highest unmet medical need, with ETD001 being well-tolerated and having expected adverse events. The company plans to advance ETD001 into longer Phase 2b studies, including combinations with CFTR modulator therapies. This milestone validates Enterprise's approach and highlights ETD001's potential for patients lacking effective treatments.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
Ethereum's price rose about 11% over the past week to around $1,920, outperforming major cryptocurrencies like Bitcoin and Solana. This rally is fueled by $96 million inflows into U.S. spot Ether ETFs early in the week, with BlackRock's ETHA product ...
The XRP Ledger has surpassed 8 million activated accounts, marking steady growth since March 2026. However, daily active addresses have declined to a 2026 low of 25,350, indicating less frequent user engagement despite overall adoption. XRP's price f...
